Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead’s oncology pipeline.
You are currently viewing a placeholder content from Elfsight. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
